Clinical Trial Results:
Pilot study to establish laboratory methods for urine Nerve Growth Factor (NGF) and immunohistochemical staining of the vanilloid receptor (TRPV1) in bladder biopsies, following open label treatment with botulinum neurotoxin type A in patients with neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO).
Summary
|
|
EudraCT number |
2010-020944-37 |
Trial protocol |
GB |
Global end of trial date |
07 Mar 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Dec 2018
|
First version publication date |
01 Dec 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
09/0127
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Joint Research Office
|
||
Sponsor organisation address |
1st floor Maple House, London, United Kingdom, W1T7DN
|
||
Public contact |
Farhat Gilani, University College London, +44 2076796469, f.gilani@ucl.ac.uk
|
||
Scientific contact |
Farhat Gilani, University College London, +44 2076796469, f.gilani@ucl.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Mar 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
07 Mar 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To establish laboratory methods for detecting changes degrees of bladder stimulation via nerves following treatment with BOTOX in patients with urinary urgency incontinence due either to:
-neurological disease
-or of unknown origin.
|
||
Protection of trial subjects |
Patients were all given PILs and went through an informed consent process prior to enrolment. Patient data was anonymised.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
14 Feb 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 25
|
||
Worldwide total number of subjects |
25
|
||
EEA total number of subjects |
25
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
25
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Males and females aged between 18 and 75 years inclusive. The group with NDO will be comprised exclusively of patients with multiple sclerosis who are attending the Uro-Neurology clinics. The group of patients with IDO will be comprised of patients without neurological disease but with urodynamically proven DO (detrusor overactivity) who ar | ||||||
Pre-assignment
|
|||||||
Screening details |
- | ||||||
Pre-assignment period milestones
|
|||||||
Number of subjects started |
25 | ||||||
Number of subjects completed |
25 | ||||||
Period 1
|
|||||||
Period 1 title |
overall trial (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
not applicable | ||||||
Arm description |
- | ||||||
Arm type |
not applicable | ||||||
Investigational medicinal product name |
OnabotulinumtoxinA
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Concentrate for solution for injection/infusion
|
||||||
Routes of administration |
Intravesical use
|
||||||
Dosage and administration details |
100U to idiopathic detrusor overactivity (10x1ml injections)
200U to neurogenic detrusor overactivity (20x1ml injections)
|
||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
not applicable
|
||
Reporting group description |
- | ||
Subject analysis set title |
clinical evaluation with ICIQ-OAB, ICIQ-LUTSqol
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
clinical evaluation with ICIQ-OAB, ICIQ-LUTSqol, and 3-day bladder diary at baseline (Visit0), 2-weeks post BTX-A (Visit1), and at return of symptoms (Visit2)
|
||
Subject analysis set title |
urinary BDNF/Creat and NGF/Creat levels
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
urinary BDNF/Creat and NGF/Creat levels also correlated with the observed clinical changes from 0.28, 0.19 and 0.29 and 0.2, 0.15, to 0.17 respectively. At the same time points decreases were also seen in BDNF and NGF bladder tissue content from 16.3, 9.14 and 11.07, and 0.41, 0.26 and 0.57 pg/g respectively.
|
|
|||||||||||||||||
End point title |
ICIQ-OAB and ICIQ-LUTSQOL scores [1] | ||||||||||||||||
End point description |
For all patients combined, across the three time points, visitO, visit1, and visit2, ICIQ-OAB scores improved at visit1 and returned to baseline by visit2, from 39.6, 13.3, and 41.3 respectively and similarly with ICIQ-LUTSqol from 193.1, 98.2 and 191.5. Similarly bladder Diary reported daily frequency episodes changed from 10.8, 6.3, 8.9, and daily urge leakage episodes changed from 6.2, 0.8, to 3 respectively over visits 1,2 and 3.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
14/2/2013 - 7/3/2015
|
||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Details provided in endpoint description |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Urinary BDNF/Creat and NGF/Creat levels | ||||||||||||||||
End point description |
At these time points urinary BDNF/Creat and NGF/Creat levels also correlated with the observed clinical changes from 0.28, 0.19 and 0.29 and 0.2, 0.15, to 0.17 respectively. At the same time points decreases were also seen in BDNF and NGF bladder tissue content from 16.3, 9.14 and 11.07, and 0.41, 0.26 and 0.57 pg/g respectively.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
february 2013 - 7/3/15
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
14/2/13-7/3/15
|
||
Adverse event reporting additional description |
2 NON SERIOUS ADVERSE EVENTS.
1 PATIENT WITH RASH - patient reported this months after treatment.
1 PATIENT WITH UTI - withdrawn from study.
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
Sponsors definitions | ||
Dictionary version |
1
|
||
Frequency threshold for reporting non-serious adverse events: 1% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: There were 2 non serious AEs One UTI and One rash post botox injection These were both reported |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |